Judge rules against AOS in bankruptcy case

Article

A recent court judgment in the American Optometric Society (AOS) bankruptcy case moved the case from Chapter 11 reorganization to Chapter 7 liquidation.

A recent court judgment in the American Optometric Society (AOS) bankruptcy case moved the case from Chapter 11 reorganization to Chapter 7 liquidation. Under Chapter 7 bankruptcy, an entity is required to stop all operations and go out of business. Then, an appointed trustee liquidates the entity’s assets in order pay off debt.

Judge Mark S. Wallace converted the case for cause, including substantial or continuing loss to or diminution of the estate and the absence of a reasonable likelihood of rehabilitation. He also stated in the ruling that there is bad faith in filing the petition and the debtor’s’ plan.

“The AOS clearly lost the lawsuit last year, and they owe us $462,000,” says Paul Ajamian, OD, chairman of the American Board of Optometry (ABO) board. “They have no plan to pay us back. They don’t have the money to pay us back. The judge saw that by calling [the lawsuit] a bad faith effort. We’ve won every legal battle along the way. We are now happy to say that it’s over. There will be a court-appointed trustee to disperse whatever assets they have. I don’t expect that they as individuals will go away and will continue to attack us.”

While the judge has ordered the dismantling of the AOS organization itself, AOS President Pamela Miller, OD, FAAO, JD, DNAP, believes that the force behind the organization remains.

“I can assure you that the AOS isn't going away by any stretch of the imagination,” Dr. Miller says. “The passion and spirit of our members continue, regardless of any organization they belong to, and that will continue to be a powerful force in our profession. We have been able to speak for the individual optometrist, who has become disenfranchised by some of the 'leaders' in organized optometry. We have exposed many truths and many lies in a dedicated effort to make our profession stronger and our sister organizations respectful and representative of their membership and optometry. We remain committed to our membership and to our desire to help bring our profession together.”

The ABO, launched in 2009, is one of several groups offering board certification to optometrists. The group is approaching 10% involvement of ODs who have taken a board-certifying exam or registered for an upcoming exam, according to Dr. Ajamian. “A lot of people are waiting in the wings because they don’t feel the need to [take the exam]. They will wait and see if they’re forced to do it. A lot of people will sit on the sidelines for anything unless they have to do it.”ODT

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.